Compare TSSI & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSSI | SRZN |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | 350 | 44 |
| Industry | Professional Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.9M | 271.6M |
| IPO Year | N/A | N/A |
| Metric | TSSI | SRZN |
|---|---|---|
| Price | $8.97 | $21.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $16.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 776.3K | 169.9K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $75.35 |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $42.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.87 | $8.21 |
| 52 Week High | $31.72 | $35.00 |
| Indicator | TSSI | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 29.49 | 38.83 |
| Support Level | $7.23 | $20.26 |
| Resistance Level | $10.02 | $24.50 |
| Average True Range (ATR) | 0.72 | 1.76 |
| MACD | -0.21 | -0.18 |
| Stochastic Oscillator | 2.75 | 22.30 |
TSS Inc provides a comprehensive suite of services for the integration of complex Artificial Intelligence (AI) technologies, planning, design, deployment, maintenance, and refresh of end-user and enterprise systems, including the mission-critical facilities that are housed. It provides a single-source solution for enabling technologies in data centers, operations centers, network facilities, server rooms, security operations centers, communications facilities, and the infrastructure systems that are critical to their functions. Services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).